The Neffy could pave the way for Canada's future in allergy care

The Big Story24mApril 21, 2026

Get the full intelligence

Search transcripts, export clips, track mentions, and explore all topics from “The Neffy could pave the way for Canada's future in allergy care” inside PodZeus.

AI-Generated Summary

This episode of The Big Story explores the recent approval of NEFI, a nasal spray version of epinephrine, by Health Canada—a breakthrough that could transform allergy care in Canada. Host Maria Kastane speaks with Dr. Mariam Hanna, a pediatric allergist and clinical immunologist, about the rising prevalence of anaphylaxis across all age groups, particularly the growing number of adults developing new-onset food, medication, and venom allergies. The discussion highlights the limitations of current treatment options, the psychological and logistical barriers to using EpiPens, and the importance of shifting from a 'diagnose and adios' model to lifelong patient empowerment. Dr. Hanna emphasizes the need for better transition support from pediatric to adult care, self-advocacy, and updated guidelines. The NEFI nasal spray offers a needle-free, fast-acting alternative that’s already in use in the U.S., with potential to increase access and reduce fear around emergency treatment. The episode also touches on emerging therapies like oral, sublingual, and epicutaneous immunotherapies, as well as the role of biologics in blocking allergic reactions. Despite progress, challenges remain around cost, access, and national policy coordination, with advocates pushing for a unified national anaphylaxis action plan. Key takeaways include: 1) The NEFI nasal spray is a game-changing, needle-free epinephrine option that could improve emergency response rates; 2) Adults with allergies often fall through the cracks after transitioning from pediatric care—self-advocacy and ongoing medical follow-up are critical; 3) New treatments like immunotherapies and biologics are expanding options beyond avoidance and epinephrine; 4) Public awareness and policy changes are needed to ensure epinephrine is available in workplaces, schools, and public spaces; 5) The approval of NEFI reflects a broader shift toward patient-centered, accessible allergy care. The episode ends with a call to action for listeners to share their experiences and help drive systemic change.

Key Takeaways
1

NEFI, a nasal epinephrine spray, offers a needle-free, equally effective alternative to EpiPens and could significantly improve emergency response rates.

2

Adults with allergies often lack support after transitioning from pediatric care—self-advocacy and regular reassessment with allergists are essential.

3

Emerging treatments like oral, sublingual, and epicutaneous immunotherapies are expanding options beyond avoidance and epinephrine.

4

Public policy and national guidelines are needed to ensure epinephrine is accessible in workplaces, schools, and public spaces.

5

The approval of NEFI marks a shift toward more accessible, user-friendly allergy care, but cost and access remain key challenges.

Chapters
0:00
2 min

The Rise of Anaphylaxis in Canada

The episode opens with a discussion on the growing prevalence of anaphylaxis in Canada, particularly among children and adults, and the urgent need for better access to emergency treatment.

2:15
3 min

Understanding Anaphylaxis: Triggers and Symptoms

Dr. Hanna explains what anaphylaxis is, its varied symptoms, and the three main triggers: food, medications, and venom, emphasizing how the immune system overreacts to harmless substances.

5:30
5 min

The Global and Canadian Allergy Epidemic

The episode examines rising allergy rates in industrialized nations, particularly Canada, and explores environmental and lifestyle factors like microbiome changes and vitamin D exposure that may contribute to this trend.

10:00
5 min

From Diagnosis to Lifelong Management

You're not just diagnosed and adios. You're managing this every single day, and you need to be empowered to advocate for yourself.

Highlight
15:00
8 min

The Future of Allergy Treatment: Beyond Epinephrine

We're not just treating symptoms anymore—we're training the immune system and blocking the reaction before it starts.

Highlight
High-Impact Quotes
We're not just treating symptoms anymore—we're training the immune system and blocking the reaction before it starts.
Dr. Mariam Hanna20:39
Viral: 90.0
The NEFI is needle-free, fast-acting, and could revolutionize how we respond to anaphylaxis—especially in settings where fear of needles has been a barrier.
Dr. Mariam Hanna23:54
Viral: 88.0
You're not just diagnosed and adios. You're managing this every single day, and you need to be empowered to advocate for yourself.
Dr. Mariam Hanna28:49
Viral: 85.0
Speakers

Host

Maria Kastane

Guest

Dr. Mariam Hanna
Topics Discussed
nefi nasal epinephrine98%anaphylaxis95%allergy care in canada90%allergy treatment innovations88%adult allergy management85%immunotherapy80%healthcare transition75%public health policy70%
People & Brands

Dr. Mariam Hanna

person

15xPositive

NEFI

product

12xPositive

Maria Kastane

person

10xNeutral

Health Canada

organization

8xPositive

EpiPen

product

7xNeutral

oral immunotherapy

other

3xPositive

sublingual immunotherapy

other

2xPositive

epicutaneous immunotherapy

other

2xPositive

biologics

other

2xPositive

National Anaphylaxis Action Plan

other

2xPositive

Get the full intelligence

Search transcripts, export clips, track mentions, and explore all topics from “The Neffy could pave the way for Canada's future in allergy care” inside PodZeus.

Start discovering podcast insights today

Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.

No credit card required • 7-day trial • Cancel anytime